English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

C hronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension classified as group IV. Pulmonary artery stenosis or obstruction by an organized thrombus can cause pulmonary hypertension, which can lead to right heart failure and death. Medical therapy, balloon pulmonary angioplasty (BPA), and pulmonary endarterectomy are recommended for the treatment of CTEPH. In recent guidelines, pulmonary endarterectomy is recommended for patients with CTEPH who are technically operable. Medical therapy or BPA is recommended for patients with CTEPH who are technically non-operable. The prognosis of patients with CTEPH depends on the degree of mean pulmonary artery pressure (PAP). The prognosis of patients with CTEPH whose mean PAP is over 30 mmHg is very poor. In other words, sufficient reduction of mean PAP by medical treatment has the potential to improve the prognosis of patients with CTEPH. Riociguat, which is a soluble guanylate cyclase stimulator, is currently available for treating CTEPH. Although riociguat has been shown to improve exercise capacity and pulmonary vascular resistance, it could not induce sufficient reduction of mean PAP. On the other hand, BPA results in a remarkable reduction of mean PAP and is expected to improve the prognosis of patients with CTEPH. Therefore, BPA should be selected for patients with CTEPH who are technically non-operable. The first full report on BPA in patients with CTEPH was published in 2001. Although it was shown that BPA improved exercise capacity and mean PAP, reperfusion pulmonary edema occurred at a high rate and the 30-day mortality rate was 5.5%. Therefore, BPA was abandoned for several years. Matsubara, et al performed BPA to reduce reperfusion pulmonary edema after BPA through a trial and error process. The use of epoprostenol to decrease mean PAP before BPA and the use of methylprednisolone and non-invasive positive-pressure ventilation after BPA could not prevent the occurrence of reperfusion pulmonary edema. From their experience with BPA, they noticed that the lung complication after BPA was not reperfusion pulmonary edema but rather vascular injury caused by a catheter-related technique. They therefore inserted the guide wire carefully and dilated an undersized balloon on the target lesion. This refined BPA technique remarkably decreased mean PAP and exercise capacity with a low rate of lung injury after BPA, and their technique is now used worldwide. However, it has not been possible to completely prevent lung injury after BPA. If the factors associated with lung injury after BPA are known, the incidence of lung injury could be decreased by addressing the factors before BPA.

Novel Predictor of Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension